ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Trends in radiation oncology between 2015 and 2022: report from a German university radio-oncology department.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHow have the demographics of radiotherapy patients changed between 2015 and 2022? What was the impact of the pandemic, of modified multidisciplinary therapy concepts, and of structural changes on our patient cohort?
methodsWe analyzed the data of all patients who underwent computed tomography-guided radiotherapy or ultrasound-planned high dose rate prostate brachytherapy at our department between 2015 and 2022. We examined tumor diagnoses in terms of frequency, age of the patients and the distance between patients' place of residence and our department.
resultsA total of 8842 patients underwent radiotherapy at our clinic between 2015 and 2022. The median age at treatment increased from 62 years in 2015 to 64 years in 2022. Within the entire cohort, 18% underwent metastasis-directed radiotherapy, 13% had radiotherapy for head and neck tumors, and 12% for breast or prostate cancer. Skin cancer treatments increased in frequency by 79% during study period, while prostate treatments rose by 10%. Overall, 47% of all patients lived within a 10-km radius of our clinic. Patients who received brachytherapy for cervical or endometrial cancer travelled significantly further. During the national epidemic emergency (03/2020 to 11/2021), there was no significant change in the long-term average number of patients or the proportion of cancer types.
conclusionThere has been a significant increase in radiotherapy treatments for skin cancer, alongside an aging patient population. Although we primarily act as a local radiotherapy partner, the increased travel distances for brachytherapy patients underscore the particular responsibility of a university radiotherapy department as a primary center and key provider of comprehensive cancer care.
Indexed as
Identifiers
42726226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.